iht DESTINY®

Sirolimus eluting
coronary stent system

TECHNICAL SPECIFICATIONS



Stent	
Material	Co Cr F562 alloy
Average strut thickness	68 µm
Stent design	Open cell and flexible structure
Inactive components	Biostable acrylic polymer
Balloon material	Nylon 12
Positioning marks	Brachial and femoral in the hypotube area
Radiopaque marks	2 gold in the balloon area
Delivery system workable length	141 cm
Entry profile	0.016”
Crossing profile	0.023”
Foreshortening	≤ 2.0 %
Radial force	≥ 0.17 N/mm²
Recoil	4.0 %

Drug / polymer	
Drug	Sirolimus (rapamycin)
Drug dose	0.90 µg/mm²

Delivery system	
Nominal pressure	6-8 bar
Rated burst pressure	17 bar
Guiding catheter compatibility	5 F for all sizes
Guide wire compatibility (max)	0.014” (0.36 mm)

REFERENCES

Diameter (mm) \ Length (mm)	8	12	15	18	23	28	32	36	40
2.0	0063208	0063202	0063205	0063218	0063203	0063210	0063212		
2.25	0063228	0063222	0063225	0063238	0063223	0063230	0063232		
2.5	0063258	0063252	0063255	0063268	0063253	0063260	0063262	0063256	
2.75	0063278	0063272	0063275	0063288	0063273	0063280	0063282	0063276	
3.0	0063308	0063302	0063305	0063318	0063303	0063310	0063312	0063306	0063304
3.5	0063358	0063352	0063355	0063368	0063353	0063360	0063362	0063356	0063354
4.0		0063402	0063405	0063418	0063403	0063410	0063412	0063406	0063404

SMALL DIAMETERS

Bibliography

1. García E *et al. Bionert stent angiographic study. Hospital General Universitario Gregorio Marañón, Madrid.* Interventional Cardiology 2008. **2.** Zhang H *et al. Solely abluminal drug release from coronary stents could possibly improve reendothelialization.* Catheter Cardiovasc Interv 2013 Dec 10. **3.** Gutiérrez-Chico JL *et al. Long-term tissue coverage of a biodegradable polylactide polymer-coated biolimus-eluting stent: comparative sequential assessment with optical coherence tomography until complete resorption of the polymer.* Am Heart J 2011 Nov; 162(5):922-31. **4.** Krucoff MW *et al*; COSTAR II Investigators Group. *A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent with Antiproliferative for Restenosis) II study.* J Am Coll Cardiol 2008 Apr 22; 51(16):1543-52. **5.** Kastrati A *et al. Intracoronary Stenting and Angiographic Results: Strut Thickness Effect on Restenosis Outcome. (ISAR-STEREO) Trial.* Circulation 2001; 103:2816-2821. **6.** Briguori C *et al. In-stent restenosis in small coronary arteries. Impact of strut thickness.* JACC 2002; 40(3):403-409. **7.** Palmaz JC *et al. Influence of surface topography on endothelialization of intravascular metallic material.* J Vasc Interv Radiol 1999; 10(4):439-444. **8.** Honari G *et al. Hypersensitivity reactions associated with endovascular devices.* Contact Dermatitis 2008; 59:7-22. **9.** Christiansen EH *et al. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V).* Lancet 2013 Feb 23; 381(9867):661-9. **10.** Maeng M *et al. 3-year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents.* JACC Cardiovasc Interv 2012 Aug; 5(8):812-8. **11.** Weisz G *et al. Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial.* J Am Coll Cardiol 2009 Apr 28; 53(17):1488-97.

Iberhospitex S.A. Avda. Catalunya, 4 - 08185 Lliçà de Vall, Barcelona, Spain
Tel +34 93 843 60 34 - Fax +34 93 843 61 11 - info@iht.es - www.iht.es

Ref: 00962099
Rev: 2020-07-30

iht DESTINY®

Sirolimus eluting
coronary stent system

IHT
Cordynamic

The
last-generation stent[1]

NEW



OVAL & ULTRATHIN STRUT DESIGN

Endo Boost TECHNOLOGY

4th GENERATION OF IHT DES CORONARY STENTS

ihtDESTiny®

Sirolimus eluting coronary stent system



IHT Cordynamic

Integral design for fast healing and better endothelialization[2,3,4]

ihtDESTiny® is a sirolimus-releasing stent system that integrates a Co Cr platform with a biostable abluminal polymer matrix.

OPEN-CELL STENT

- Improves longitudinal flexibility.
- Optimises crossing capacity and radial force.



ULTRATHIN DESIGN (68 µm)

Co Cr F562 platform.[7,8]

HYDRODYNAMIC LOW PROFILE STRUT

Endo Boost TECHNOLOGY

- Oval and ultrathin strut design.
- Minimal flow disturbance improves long-term safety.[5,6]



ABLUMINAL SIROLIMUS COATING

- Cytostatic drug.
- Drug dose 0.9 µg/mm².



POLYMER (BA-co-THEMA)

- Fluoropolymer design for DES long-term safety.



ABLUMINAL DUAL-LAYER BIOSTABLE COATING

- Designed for DES use.
- Developed and manufactured by IHT.
- Abluminal dual-layer release control.